Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma.
Hironao OkuboHitoshi AndoKei IshizukaRyuta KitagawaShoki OkuboHiroaki SaitoShigehiro KokubuAkihisa MiyazakiKenichi IkejimaShuichiro ShiinaAkihito NagaharaPublished in: PloS one (2020)
Longitudinal assessments of carnitine and fatigue in patients with hepatocellular carcinoma suggest that lenvatinib affects the carnitine system in patients undergoing lenvatinib therapy and that carnitine insufficiency increases fatigue. The occurrence of carnitine insufficiency may be a common cause of fatigue during the treatment.